Erasca, Inc.
ERAS
Rangering i aksjer
#3608
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Aksjekurs
$13.75
Markedsverdi
$4.81B
Endring (1 dag)
2.65%
Endring (1 år)
467.98%
Land
US
Handel Erasca, Inc. (ERAS)
Kategori
Healthcare
EPS for Erasca, Inc. (ERAS)
EPS per June 2026 TTM: $-0.95
Ifølge de siste økonomiske rapportene og aksjekursen til Erasca, Inc. er selskapets nåværende EPS (TTM) $-0.95. Ved slutten av 2023 hadde selskapet en EPS på $-0.83, en nedgang sammenlignet med EPS-en i 2022 som var $-1.99.
EPS-historikk for Erasca, Inc. fra 2019 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $-0.95 | 37.68% |
| 2024 | $-0.69 | -16.87% |
| 2023 | $-0.83 | -58.29% |
| 2022 | $-1.99 | 93.20% |
| 2021 | $-1.03 | 21.18% |
| 2020 | $-0.85 | 750.00% |
| 2019 | $-0.10 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | -1,923.16% |
US
|
|
| $-7.98 | 740.00% |
US
|
|
| $-5.29 | 456.84% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -3,020.00% |
NL
|
